Clearmind Medicine to move forward with MEAI-based alcohol substitute
Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health ...
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CMND), (FSE: CWY0 ...
Morningstar2d
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine ...
Clearmind Medicine receives IRB approval for Phase I/IIa trial of CMND-100
Clearmind Medicine (CMND) announced it has received Institutional Review Board approval for its Phase I/IIa clinical trial of CMND-100, ...
Clearmind Medicine Shares Double on Trial Approval
Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...
Clearmind Medicine Inc.: Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...
Nasdaq4d
Clearmind Medicine Inc. Receives IRB Approval for Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Inc., a clinical-stage biotech company focused on psychedelic-derived therapeutics, has announced the receipt of Institutional Review Board approval for its Phase I/IIa clinical ...